BioCentury | Aug 28, 2020
Distillery Therapeutics

Potassium channel-vesicle interaction as a target in ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Interrupting the interaction between the potassium channel KCNB1 and VAPA, a vesicle membrane protein, could treat ischemic stroke. In cultured rat cortical...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Activating potassium channel KCNJ3 to treat epilepsy

DISEASE CATEGORY: Neurology INDICATION: Epilepsy A thiophenylurea-based activator of the potassium channel KCNJ3 could treat epilepsy. In a mouse model of chemically induced epilepsy, the KCNJ3 activator reduced seizure severity and the duration of tonic...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

...subtypes with a mutation on an undisclosed target in the TBK1 autophagy pathway; another targeting potassium channels...
BioCentury | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's neurology portfolio and gives...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

Lung Therapeutics closes $36M series C Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53...
BioCentury | May 15, 2019
Translation in Brief

Lentiviral gene therapy could offer relief to refractory epilepsy patients

Within a year, University College London researchers hope to begin a clinical trial of a gene therapy for epilepsy, a non-monogenic disorder. The hope is that the approach will offer an alternative to brain surgery...
BioCentury | May 14, 2019
Distillery Techniques

A mouse model to screen therapies for Williams syndrome

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Transgenics and knockouts GTF2I-deficient mice could be used to screen therapies for Williams syndrome, which is caused by gene deletions on chromosome 7 that lead to learning and cardiovascular problems....
Items per page:
1 - 10 of 437